IP Library Granted Patent US 7,186,399
Granted Patent B2
US 7,186,399 · App. 10/302,369 · Granted Mar 6, 2007

Methods for targeted drug delivery

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,186,399
App. No.
10/302,369
Granted
Mar 6, 2007
Kind
B2
Abstract

A method for ligand-based binding of lipid encapsulated particles to molecular epitopes on a surface in vivo or in vitro comprises sequentially administering (a) a site specific ligand activated with a biotin activating agent; (b) an avidin activating agent; and (c) lipid encapsulated particles activated with a biotin activating agent, whereby the ligand is conjugated to the particles through an avidin-biotin interaction and the resulting conjugate is bound to the molecular epitopes on such surface. The conjugate is effective for imaging by x-ray, ultrasound, magnetic resonance or positron emission tomography. Compositions for use in ultrasonic imaging of natural or synthetic surfaces and for enhancing the acoustic reflectivity thereof are also disclosed.

Claims (17)

1. A method to effect delivery of a therapeutic agent into a target tissue of a subject in vivo which method comprises

(a) administering to said subject an emulsion of particles that consist of lipid-coated liquid perfluorocarbon and at least one therapeutic agent which particles are directly coupled to a ligand specific for said target tissue, and

(b) delivering said therapeutic agent to said target tissue while said particles are entirely in the liquid state.

2. The method of claim 1 wherein said ligand comprises an antibody or fragment thereof, a virus, a receptor agonist or antagonist, a hormone, or a nucleic acid.

3. The method of claim 2 wherein the ligand comprises an antibody or fragment thereof or a receptor agonist or antagonist.

4. The method of claim 3 wherein the ligand is an antibody or fragment thereof.

5. The method of claim 1 wherein the therapeutic agent is a drug or a radioactive agent.

6. The method of claim 5 wherein the drug is tissue plasminogen activator, adriamycin, vincristine, urokinase, streptokinase, methotrexate, cytarabine, thioguanine, 5-fluorouracil, cisplatin, etoposide, ifosfamide, asparaginase, deoxycoformycin or hexamethyl melamine.

7. The method of claim 1 which further comprises obtaining an ultrasonic image or magnetic resonance image of said target tissue.

8. The method of claim 1 wherein said target tissue is a thrombus or cancer.

9. An emulsion which comprises particles consisting of liquid perfluorocarbon coated with lipid and at least one therapeutic agent, wherein said particles are directly coupled to a ligand specific for a target tissue, wherein said perfluorocarbon consists of perfluorotributylamine, perfluorodecalin, perfluorooctylbromide, perfluorodichlorooctane, perfluorodecane, perfluorotripropylamine, perfluorotrimethylcyclohexane, or mixtures of the foregoing.

10. The emulsion of claim 9 wherein said ligand comprises an antibody or fragment thereof, a virus, a receptor agonist or antagonist, a hormone, or a nucleic acid.

11. The emulsion of claim 10 wherein the ligand comprises an antibody or fragment thereof or a receptor agonist or antagonist.

12. The emulsion of claim 11 wherein the ligand is an antibody or fragment thereof.

13. The emulsion of claim 9 wherein the therapeutic agent is a drug or a radioactive agent.

14. The emulsion of claim 13 wherein the drug is tissue plasminogen activator, adriamycin, vincristine, urokinase, streptokinase, methotrexate, cytarabine, thioguanine, 5-fluorouracil, cisplatin, etoposide, ifosfamide, asparaginase, deoxycoformycin or hexamethyl melamine.

15. The method of claim 1 wherein said perfluorocarbon consists of perfluorotributylamine, perfluorodecalin, perfluorooctylbromide, perfluorodichlorooctane, perfluorodecane, perfluorotripropylamine, perfluorotrimethylcyclohexane, or mixtures of the foregoing.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded May 3, 2010
From: PROLOG CAPITAL II, L.P.; CHARTER LIFE SCIENCES, L.P.; MEMPHIS BIOMED VENTURES II, L.P.; TRIATHLON MEDICAL VENTURES FUND, L.P.; ADVANTAGE CAPITAL COMMUNITY DEVELOPMENT FUND XV, LLC; ALAFI CAPITAL COMPANY, LLC; APJOHN VENTURES FUND, LP; VECTIS LIFE SCIENCES FUND I, L.P.; WICKLINE, SAMUEL A., M.D.; 1998 CO-INVESTING LLC; C. AGANOSTOPOULOS REVOCABLE TRUST U/A 12/21/1978
To: KEREOS, INC.
Reel/Frame 024320/0741 →
SECURITY AGREEMENT Recorded Jul 17, 2009
From: KEREOS, INC.
To: PROLOG CAPITAL II, L.P.; CHARTER LIFE SCIENCES, L.P.; MEMPHIS BIOMED VENTURES II, L.P.; TRIATHLON MEDICAL VENTURES FUND L.P.; ADVANTAGE CAPITAL COMMUNITY DEVELOPMENT FUND XV, LLC; ALAFI CAPITAL COMPANY, LLC; APJOHN VENTURES FUND, LP; VECTIS LIFE SCIENCES FUND I, L.P.; WICKLINE, SAMUEL A., M.D.; 1998 CO-INVESTING LLC; C. AGANOSTOPOULOS REVOCABLE TRUST U/A 12/21/1978
Reel/Frame 022960/0670 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 6, 2006
From: LANZA, GREGORY M.; WICKLINE, SAMUEL A.
To: BARNES-JEWISH HOSPITAL
Reel/Frame 018608/0586 →